Trelegy Cost in 2026: Prices and How to Save

If you've picked up your Trelegy inhaler and watched the register climb past $600, you already know the problem. One small purple inhaler. Thirty days. Hundreds of dollars. And you need a new one next month.

Trelegy cost is one of the most common sticker shocks in respiratory care right now, and it's not because you're doing anything wrong. There's still no generic, the inhaler combines three drugs in one device, and the brand has the U.S. market largely to itself. The price reflects that. But the amount you pay isn't fixed — it changes a lot depending on where and how you buy.

How much does Trelegy cost without insurance?

The short answer: more than almost any other maintenance inhaler on the market.

Trelegy Ellipta carries a manufacturer list price of about $698 per inhaler as of January 2026. That list price is the starting point, not the final number. What you actually pay at the counter depends on your pharmacy's markup, your location, and whether any cash discount applies.

Here's roughly what a single 30-day Trelegy inhaler costs without insurance at common U.S. pharmacies in 2026:

Where you buy	Approximate cash price (30-day inhaler)
Manufacturer list price	~$698
Large chain pharmacies (CVS, Walgreens, Walmart)	~$800–$900
Discount-card price at some pharmacies	~$580–$700
Cross-border cash-pay (e.g., CanAmerica Plus)	~$77 per month

Both Trelegy strengths — the 100/62.5/25 mcg used for COPD and asthma, and the 200/62.5/25 mcg used only for asthma — sit in the same price range. Switching strengths won't save you money. The number of doses will: a standard inhaler holds 30 doses, a 30-day supply at the usual once-daily dose.

Stretch that across a year and the math gets heavy. At $700 a month, you're looking at roughly $8,400 annually for one prescription. For people on fixed incomes or managing more than one chronic condition, that's not a line item — it's a decision about which medication to skip.

Why is Trelegy so expensive?

Three reasons, and they reinforce each other.

First, Trelegy packs three separate medications into one inhaler: fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-agonist). Single-inhaler triple therapy is convenient and clinically useful, but you're paying for the combination and the Ellipta delivery device, not just the drugs.

Second, there's no competition. With no generic on the U.S. market, GSK sets the price without a lower-cost equivalent pulling it down. Trelegy brought in close to $2.7 billion in U.S. net sales in 2024, which tells you how much room the brand has to hold its pricing.

Third, the patent wall is real. Multiple patents protect the formulation and device, and they don't start expiring in a way that clears the path for generics until the end of the decade.

None of that helps your monthly budget. But it explains why the price hasn't budged — and why it probably won't until generics actually arrive.

Is there a generic for Trelegy?

Not yet. And not soon, despite some recent movement worth knowing about.

In January 2026, Transpire Bio announced that the FDA accepted its abbreviated new drug application (ANDA) for a generic version of fluticasone furoate, umeclidinium, and vilanterol — the three ingredients in Trelegy. The company says it was first to file with a Paragraph IV patent challenge, which is the legal step generic makers use to try to enter before all patents expire.

That's a real development, but "accepted for filing" is the beginning of a long process, not a launch date. Trelegy is shielded by six patents, and the earliest projected date for generic entry is around November 2030. Legal challenges could shift that in either direction. For now, anyone telling you a cheap generic Trelegy is around the corner is getting ahead of the facts.

How to save on Trelegy

Since the price is locked in at the brand level, real savings come from changing the channel you buy through or the inhaler you take. Here are the approaches that actually move the number.

Compare cash-pay and cross-border pharmacy prices

The gap here is wider than with any other savings move. U.S. retail for Trelegy hovers near $700 a month. Through a cash-pay cross-border network, the same medication often costs a fraction of that.

For example, Trelegy Ellipta through CanAmerica Plus runs about $229.99 for a 90-day supply — roughly $77 a month, compared with a U.S. cash price closer to $1,700 for the same 90 doses. That's a difference of more than $1,400 over three months for the identical inhaler.

Cash-pay pricing works the same way whether or not you have insurance, which makes it useful for people in the Medicare "donut hole," those with high-deductible plans, or anyone whose plan doesn't cover Trelegy well. Always confirm you're ordering through a licensed, verified pharmacy and that a valid prescription is on file.

Ask your doctor about therapeutic alternatives

Trelegy isn't the only inhaler in its lane. Depending on your diagnosis — COPD or asthma — a different combination may control your symptoms at a lower cash price. None of these are interchangeable on your own — this is a conversation for your prescriber — but knowing the options helps you have it.

Inhaler	Drug classes	Typical use	Relative cash cost vs. Trelegy
Trelegy Ellipta	ICS + LAMA + LABA (triple)	COPD, asthma	Baseline (highest)
Breztri Aerosphere	ICS + LAMA + LABA (triple)	COPD	Comparable (triple therapy)
Breo Ellipta	ICS + LABA (dual)	COPD, asthma	Lower
Symbicort	ICS + LABA (dual)	COPD, asthma	Lower, generic available
Advair Diskus	ICS + LABA (dual)	COPD, asthma	Lower, generic available

The two-drug inhalers won't suit everyone — Trelegy's third ingredient exists for a reason, especially in COPD with frequent flare-ups. But for some patients, a dual-therapy inhaler delivers most of the benefit at a far lower price, and several have generic versions. Through cash-pay pricing, Breo, Symbicort, and Advair land in the range of roughly $45 to $55 a month — below even Trelegy's discounted cash price. If you genuinely need triple therapy, Breztri is the closest equivalent to Trelegy.

Don't count on a discount card to fix the whole bill

Pharmacy discount programs can shave something off the retail price, and they're worth checking. But they rarely take a $700 inhaler down to a comfortable number. For a drug this expensive with no generic, the bigger lever is almost always the cash-pay channel or a lower-cost alternative — not a coupon at the same pharmacy.

What Trelegy actually does

Worth a quick grounding, since the price only makes sense alongside what you're buying.

Trelegy Ellipta is a once-daily maintenance inhaler for adults. The 100/62.5/25 mcg strength treats chronic obstructive pulmonary disease (COPD) — including chronic bronchitis and emphysema — and also asthma. The 200/62.5/25 mcg strength is for asthma only. It combines an inhaled steroid to reduce airway inflammation, a muscarinic antagonist to relax airway muscles, and a long-acting beta2-agonist to keep airways open.

It is not a rescue inhaler. It won't help a sudden attack, and it doesn't replace a fast-acting albuterol inhaler — or a nebulized treatment like DuoNeb that some COPD patients keep on hand for flare-ups. Common side effects include sore throat, headache, sinus infection, and back pain; more serious risks include pneumonia, worsening glaucoma or urinary retention, and increased heart rate. If you've had a Trelegy supply gap during the periodic inhaler shortages reported in 2026, don't simply stop — talk to your pharmacist or doctor about a bridge option.

The bottom line

Trelegy is expensive because it's a three-in-one inhaler with no generic and strong patent protection, and that won't change in a meaningful way until around 2030. What you can change today is how you buy it. A cash-pay cross-border option can take the cost from roughly $700 a month to about $77, and a different inhaler in the same drug classes may save even more. Check a verified cash-pay price on Trelegy Ellipta, and bring the alternatives to your next appointment so you and your doctor can decide what fits.

Frequently asked questions

How much does Trelegy cost per month without insurance?

At major U.S. pharmacies, a 30-day Trelegy inhaler costs roughly $580 to $900 without insurance, with a list price near $698 as of early 2026. Cash-pay cross-border pharmacies can lower that to about $77 a month for the same inhaler.

Is there a generic version of Trelegy?

No FDA-approved generic is available in 2026. A generic application was accepted for FDA review in January 2026, but because of patent protections, the earliest likely launch is around 2030.

Why is Trelegy so expensive?

It combines three medications in one inhaler device, faces no generic competition, and is protected by multiple patents. With U.S. sales near $2.7 billion in 2024, there's little market pressure to lower the price.

Is Trelegy cheaper through a cash-pay or Canadian pharmacy?

Often, yes. Cross-border cash-pay pricing frequently runs far below U.S. retail — about $77 a month through CanAmerica Plus versus roughly $700 domestically. Use only licensed, verified pharmacies and keep a valid prescription on file.

What is a cheaper alternative to Trelegy?

Dual-therapy inhalers like Symbicort or Advair (both with generic versions) cost less and may control symptoms for some patients. Breztri Aerosphere is the closest triple-therapy alternative. Any switch should be decided with your doctor.

---

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.